• Fluorescein TSA Fluorescence System Kit Guide

  2026-09-21

  Learn how to apply tyramide-based fluorescence amplification to difficult IHC, ICC, and ISH targets without sacrificing spatial context. This practical guide connects the kit to proximity-based spatial proteomics, with workflow parameters, assay controls, and troubleshooting strategies for low-abundance biomolecule detection.

• D-N-Acetylgalactosamine: Protocol and QC Guide

  2026-09-21

  D-N-Acetylgalactosamine (SKU B7904) provides a defined, high-purity reagent for glycoprotein and brain heteropolysaccharide workflows where solvent compatibility and controlled storage are important. It is suitable for aqueous or validated DMSO preparations, but not for ethanol-based protocols or long-term storage of prepared solutions.

• α-Bungarotoxin: Nicotinic Receptor Blockade

  2026-09-20

  α-Bungarotoxin is a high-affinity α7 nicotinic acetylcholine receptor antagonist used to study nicotinic receptor blockade and cholinergic signaling. In a rat placental ischemia model, α-bungarotoxin removed pyridostigmine-associated effects, supporting α7 receptor involvement without demonstrating clinical efficacy.

• Cy3-UTP for Nuclear Speckle RNA Mapping

  2026-09-19

  Cy3-UTP enables a structure-aware approach to fluorescent RNA experiments inspired by new findings on Alu-containing RNAs and nuclear speckles. This guide connects in vitro transcription RNA labeling with mechanistic controls for RNA organization, RNA-protein binding, and fluorescence imaging of RNA.

• Syringin Enhances Sunitinib in Renal Cell Carcinoma

  2026-09-18

  A 2024 Journal of Functional Foods study identifies syringin as a natural-product candidate that suppresses renal cell carcinoma behavior and increases cellular sensitivity to sunitinib. By combining network pharmacology, molecular docking, cell-based assays, and pathway analysis, the work connects these effects to EGFR/PI3K/Akt signaling while highlighting important limits for translation beyond in vitro research.

• Hesperadin for Reliable Mitotic Assays

  2026-09-18

  This scenario-based guide explains how Hesperadin (SKU A4118) can serve as a mechanistic Aurora B kinase inhibitor control in proliferation, cytotoxicity, and cell-cycle assays. It connects biochemical potency, mitotic phenotypes, stock preparation, and vendor-selection considerations to more interpretable laboratory data.

• Patient-Derived Colorectal Organoids: A Practical Guide

  2026-09-17

  This 2025 protocol paper presents a standardized workflow for generating patient-derived colorectal organoids from normal crypts, polyps, and tumors. Its practical contribution is the integration of tissue processing, crypt isolation, culture establishment, apical-out conversion, immunofluorescence characterization, quality control, and troubleshooting for translational research.

• Docosahexaenoic Acid: From Membrane to Assay

  2026-09-17

  Explore how Docosahexaenoic Acid (DHA) connects membrane biology, neuroprotection research, and oxidation-conscious assay design. This evidence-calibrated guide distinguishes established DHA mechanisms from hypotheses inspired by recent arachidonic acid immunology findings.

• N1-Methylpseudo-UTP: From RNA Design to Translation

  2026-09-16

  N1-Methyl-Pseudouridine-5'-Triphosphate is more than a transcription reagent: it is an upstream variable that can shape RNA structure, stability, translation, and experimental interpretation. This thought-leadership analysis connects modified RNA production with mechanistic lessons from R2 retrotransposon insertion research while defining a practical validation strategy for translational teams.

• A Transient Conformation in Adenine Riboswitch Binding

  2026-09-16

  Wu and colleagues used stopped-flow fluorescence with position-selective RNA labeling to resolve ligand-induced conformational changes in the full-length adenine riboswitch. Their results identify a short-lived intermediate with an unwound P1 helix and show that P1 responds to adenine before the binding pocket and P4, refining models of riboswitch folding and ligand recognition.

• Plk1–p31comet Control of Mitotic Checkpoint Disassembly

  2026-09-15

  The reference study identifies Polo-like kinase 1 as a direct regulator of p31comet, showing that phosphorylation at Ser102 suppresses TRIP13-assisted disassembly of mitotic checkpoint complexes. This mechanism explains how cells avoid simultaneously assembling and dismantling checkpoint complexes during an active spindle assembly checkpoint, and it provides a useful framework for interpreting mitotic kinase perturbation experiments.

• TBXA2R–ERM Signaling in TNBC Metastasis

  2026-09-15

  The reference study identifies TBXA2R as a GPCR that activates ERM cytoskeletal proteins through Gαq/11, Gα12/13, Rho GTPases, and the kinases SLK and LOK. Its findings connect receptor signaling to triple-negative breast cancer motility, invasion, and metastatic colonization, providing a mechanistic framework for studying how GPCRs control metastatic behavior.

• Fluo-4 AM Maps Calcium in Diabetic Nephropathy

  2026-09-14

  A translational framework for using Fluo-4 AM to interrogate the AT1R/Ca2+ axis, validate podocyte mechanisms, and strengthen diabetic nephropathy research beyond a conventional calcium assay.

• ASCC3 Activation in Fragile X Syndrome

  2026-09-14

  A 2025 Science Translational Medicine study identifies ASCC3-dependent ribosome-associated quality control as a previously underappreciated function of FMRP and shows that CRISPR activation of ASCC3 improves molecular, synaptic, and behavioral phenotypes in Fmr1 knockout mice. The work provides a mechanistic rationale for targeting collided-ribosome handling while emphasizing that the approach remains a preclinical proof of concept.

• BI 2536 Workflows for PLK1 Inhibition

  2026-09-13

  BI 2536 enables selective interrogation of PLK1-driven mitotic control, but its greatest value comes from pairing cell-cycle measurements with time-resolved viability and death assays. This workflow connects biochemical potency, cellular response, and tumor xenograft model design while helping researchers avoid common interpretation and solubility errors.

8513 records 1/568 page Next 12345 下5页 Last page